• Radha Gopalaswamy, Nandhini Palani, Dinesh Viswanathan, Bershila Preysingh, Suchithra Rajendran, Vaishnavee Vijayaraghavan, Kannadasan Thangavel, Senthil Devi Vadivel, Hannah Stanley, Kannan Thiruvengadam, Lavanya Jayabal, Kaleeswari Murugesan, Sridhar Rathinam, Asha Frederick, Gomathi Sivaramakrishnan, Chandrasekaran Padmapriyadarsini, and Sivakumar Shanmugam.
• ICMR-National Institute for Research in Tuberculosis, Chennai 600031, India.
• Medicina (Kaunas). 2023 May 23; 59 (6).

AbstractBackground: Patients with first-line drug resistance (DR) to rifampicin (RIF) or isoniazid (INH) as a first-line (FL) line probe assay (LPA) were subjected to genotypic DST using second-line (SL) LPA to identify SL-DR (including pre-XDR) under the National TB Elimination Program (NTEP), India. SL-DR patients were initiated on different DR-TB treatment regimens and monitored for their outcomes. The objective of this retrospective analysis was to understand the mutation profile and treatment outcomes of SL-DR patients. Materials and Methods: A retrospective analysis of mutation profile, treatment regimen, and treatment outcome was performed for SL-DR patients who were tested at ICMR-NIRT, Supra-National Reference Laboratory, Chennai between the years 2018 and 2020. All information, including patient demographics and treatment outcomes, was extracted from the NTEP Ni-kshay database. Results: Between 2018 and 2020, 217 patients out of 2557 samples tested were identified with SL-DR by SL-LPA. Among them, 158/217 were FQ-resistant, 34/217 were SLID-resistant, and 25/217 were resistant to both. D94G (Mut3C) of gyrA and a1401g of rrs were the most predominant mutations in the FQ and SLID resistance types, respectively. Favorable (cured and treatment complete) and unfavorable outcomes (died, lost to follow up, treatment failed, and treatment regimen changed) were recorded in a total of 82/217 and 68/217 patients in the NTEP Ni-kshay database. Conclusions: As per the testing algorithm, SL- LPA is used for genotypic DST following identification of first-line resistance, for early detection of SL-DR in India. The fluoroquinolone resistance pattern seen in this study population corelates with the global trend. Early detection of fluoroquinolone resistance and monitoring of treatment outcome can help achieve better patient management.

21 keywords...

hide…